Assessment of tumor weight at the end of the treatment period showed average tumor weights control group were 658.75 ± 109.94 mg, asparaginase group were 500.00 ± 84.41 mg, anti-PD-L1 group were 396.25 ± 95.78 mg, and combination therapy group were 167.51 ± 21.65 mg. The gene discussed is CD274; the disease is neoplasm.